EQS-News: Cannovum AG
/ Key word(s): Miscellaneous/Research Update
Berlin, 15.12.2022 - The share of Cannovum AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has been included in trading on the Xetra and Frankfurt Stock Exchange. This means that Cannovum AG is now represented on Germany's largest and most important stock exchange.
"This is an important milestone on our way to becoming one of the market leaders in the upcoming legal cannabis segment," says Pia Marten, CEO and co-founder of Cannovum AG. "By listing on the most important German trading platform, we increase Cannovum AG's visibility in the capital markets and make it easier for investors to profit from cannabis legalization."
Even before the listing on the Xetra market, the first analysts reported on Cannovum AG's stock. From Sphene Capital, an independent research firm for small and mid caps, the share has received a Buy rating with a price target of 15.30 euros.
Contact: Klaus Madzia, IR & PR, Cannovum AG Phone +49 30 3982 163 62, klaus.madzia@cannovum.com
Cannovum AG is the first German fully licensed cannabis company listed on the stock exchange. The shares are traded on the stock exchanges in Frankfurt/Xetra, Düsseldorf, Munich, Berlin, Hamburg and gettex. Cannovum AG is ready for the legalization of cannabis and well-prepared: both for sales through pharmacies and through licensed specialty stores and online shipping.
Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer, and manufacturer of high-quality medical cannabis products based in Berlin. Already today, Cannovum AG is a market leader in the medical cannabis sector.
Currently the company works on the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for simplified and equitable access to cannabis-based therapies.
For more information, visit https://cannovum.com/investor-relations
15.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Cannovum AG |
Rheinsberger Str. 76/77 | |
10115 Berlin | |
Germany | |
Phone: | +49 (0)30 3982 16360 |
E-mail: | ir@cannovum.com |
Internet: | www.cannovum.com |
ISIN: | DE000A2LQU21 |
WKN: | A2LQU2 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt, Hamburg, Munich |
EQS News ID: | 1513363 |
End of News | EQS News Service |
|
1513363 15.12.2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.